Resetting the innovation landscape for pain and addiction therapeutics

The last five years have been challenging for pain R&D. A new study from BIO found that 77% of clinical drug programs active in 2017 are no longer active today. However, new therapies and new targets have entered the clinic during this time as companies remain determined to find innovative solutions for chronic pain. For addiction therapeutics, BIO found that the number of clinical drug programs for addiction increased over the five years. This panel will explore innovation in pain and addiction therapeutics, covering both recent clinical failures and promising therapies to watch over the next five years.